L3VLUP
ProSign in

ONC in the 13F filings

Beone Medicines LTD · CUSIP 07725L102

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Quarter end
31 Dec 2024
the date the book describes
Filed
14 Feb 2025
latest of these filings; the earliest 31 Jan 2025
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q3 2024 and Q4 2024; 4 listed it in both
Shares listed
6,889,113
combined, among listed positions
Reported value
$1.3bn
combined, at the quarter end

Among the 94 comparable managers: 2 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing ONC in Q4 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Baillie Gifford & Co3,671,195$678m0.52%Trimmed-34,56131 Jan 2025 (the filing on sec.gov)
T. Rowe Price Associates Inc2,937,170$543m0.06%Added+237,08214 Feb 2025 (the filing on sec.gov)
Artisan Partners LP279,648$52m0.08%Added+79,81012 Feb 2025 (the filing on sec.gov)
Farallon Capital Management LLC1,100$203kunder 0.1%Held014 Feb 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2024 to Q4 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
7 in Q3 2024 to 12 in Q2 2026

Tracked managers listing it, at least.

05101520162017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ONC by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20162$3.0mn.a.n.a.
Q2 20161$2.0mn.a.n.a.
Q3 20161$2.1mn.a.n.a.
Q4 20161$2.1mn.a.n.a.
Q1 20171$2.6mn.a.n.a.
Q2 20171$3.3mn.a.n.a.
Q3 20174$812mn.a.n.a.
Q4 20173$822mn.a.n.a.
Q1 20187$2.0bnn.a.n.a.
Q2 20188$1.7bnn.a.n.a.
Q3 20189$2.1bnn.a.n.a.
Q4 20185$1.3bnn.a.n.a.
Q1 20193$1.1bnn.a.n.a.
Q2 20194$1.0bnn.a.n.a.
Q3 20193$1.1bnn.a.n.a.
Q4 20194$1.3bnn.a.n.a.
Q1 20203$993mn.a.n.a.
Q2 20205$1.7bnn.a.n.a.
Q3 20205$2.9bnn.a.n.a.
Q4 20209$2.9bnn.a.n.a.
Q1 20219$4.7bnn.a.n.a.
Q2 20219$4.2bnn.a.n.a.
Q3 20216$4.4bnn.a.n.a.
Q4 20216$3.2bnn.a.n.a.
Q1 20224$2.0bnn.a.n.a.
Q2 20224$1.5bnn.a.n.a.
Q3 20225$1.2bnn.a.n.a.
Q4 20226$2.1bnn.a.n.a.
Q1 20237$1.8bnn.a.n.a.
Q2 20236$1.5bnn.a.n.a.
Q3 20234$1.7bnn.a.n.a.
Q4 20232$1.0bn11
Q1 20244$926m31
Q2 20247$949m61
Q3 20247$1.6bn52
Q4 20244$1.3bn22
Q1 202514$3.4bn122
Q2 20256$1.3bn27
Q3 20258$2.1bn43
Q4 20259$1.8bn158
Q1 20269$2.1bn198
Q2 202612$2.5bn1612

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ONC and LLY →ONC and JNJ →ONC and VRTX →Choose a stock to compare with ONC →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ONC, latest filings →Back to the 13F Explorer →